Effect and clinical research summary of vorasidenib-VORANIGO in the treatment of vulvovaginal candidiasis

Vorasidenib (trade name: VORANIGO) is a new type of oral drug that belongs to the category of targeted inhibitors. Its main research direction was initially focused on IDH1/2 mutant gliomas and some hematological tumors. Recent studies have attempted to evaluate its potential application in vulvovaginal candidiasis (VVC). Vulvovaginal candidiasis is a common gynecological fungal infection, mainly caused by Candida albicans. It manifests symptoms such as itching, burning, abnormal leucorrhea, and local redness and swelling. Although traditional antifungal drugs such as fluconazole, itraconazole, and nystatin are commonly used for treatment, treatment challenges still exist in some recurrent or drug-resistant cases, so the research of new targeted drugs has attracted attention.

In clinical studies, the potential efficacy of vorsidenib on VVC mainly works through its mechanism of regulating the host's local immune response and inhibiting fungal metabolism. Animal model studies have shown that vorsidenib can inhibit the growth of Candida in local tissues, while reducing the secretion of fungus-related inflammatory factors, thereby alleviating local symptoms. Preliminary in vitro experiments also show that voxanib can inhibit some fluconazole-resistant strains, suggesting that it may have therapeutic potential in patients with drug-resistant VVC.

Clinical trial data are still in the early stages, but some Phase I and II studies have shown that oral administration of vorsidenib can relieve patients' symptoms of vulvar itching and abnormal leucorrhea within a few days. Among patients treated with vorsidenib, most fungal cultures were negative after the course of treatment, and the recurrence rate was slightly lower than that in the control group. In addition, the drug is well tolerated. Common adverse reactions are mild to moderate gastrointestinal discomfort and mild headache. The incidence of serious adverse events is low, which provides a preliminary safety basis for clinical promotion.
The clinical application of vorsidenib in the treatment of VVC still needs to be verified by more high-quality studies. Future research directions include optimizing dosage and dosing regimens, determining efficacy in patients with long-term recurrent VVC, the potential for combination with existing antifungal drugs, and sensitivity analysis of the drug to different Candida strains. At the same time, drug metabolism, local tissue concentration and impact on host immunity also need to be further explored to achieve precise medication in clinical practice. In general, vorsidenib, as a new targeted drug, provides a potential treatment option for patients with drug-resistant or recurrent vulvovaginal candidiasis. However, large-scale randomized controlled clinical trials are still needed to further verify its efficacy and safety and lay a solid foundation for future promotion and application.
Reference: https://www.drugs.com/